A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer(TORG1632).
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TORG1632
- 01 Nov 2021 Results assessing the efficacy, safety and plasma concentrations of low dose afatinib monotherapy in patients with EGFR mutation-positive non-small cell lung cancer, published in the Lung Cancer.
- 26 Nov 2020 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Primary endpoint (Progression Free Survival) has been met according to the results presented at the 45th European Society for Medical Oncology Congress